The viral vectors-based gene therapy for non-human primates market is experiencing significant growth, driven by advancements in gene therapy techniques and increasing research into genetic disorders and therapies for complex diseases. Non-human primates (NHPs) are crucial in preclinical studies, offering vital insights into the safety and efficacy of viral vector-based therapies before human trials. The market is bolstered by the rising prevalence of chronic diseases and genetic disorders, along with the need for innovative treatment solutions. Furthermore, the development of cutting-edge viral vectors, such as adeno-associated viral (AAV) vectors and lentiviral vectors, is enhancing therapeutic potential, expanding application areas, particularly in oncology and neurological disorders. Overall, the market's growth trajectory is supported by collaborations between pharmaceutical companies, biotechnology firms, and research institutions focused on developing effective gene therapies.
